Lv1
10 积分 2025-07-15 加入
Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials
2个月前
已关闭
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
4个月前
已完结
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
8个月前
已完结
皖公网安备34019202002308
